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Axillary lymph node status is the most important prognostic factor 
in breast cancer. Prognosis decreases as the number of tumor-
positive lymph nodes increases (1). In 1948, Saphir and Amromin 
(2) reported that a limited number of sections, instead of many 
sections, taken from axillary lymph nodes were not sufficient to 
determine whether metastases were present or absent. They seri-
ally sectioned lymph nodes that showed no tumor in random sec-
tions and called the metastases that were so discovered “obscure” 
axillary lymph node metastases. Since then, the presence of tumor 
deposits in axillary lymph node dissection specimens that were 
initially assessed as negative on routine histological examination 
has been reported (3–11). In these studies, the frequency of such 
occult metastases has varied widely, but their prognostic value has 
remained unclear. In daily clinical practice, moreover, examining 
all axillary lymph nodes by serial sectioning is not feasible.
This view changed soon after introduction of the sentinel 
lymph node procedure in the late 1990s (12). To prevent false-
negative results and undertreatment, the limited numbers of 
lymph nodes removed by the sentinel lymph node procedure are 
now routinely examined by use of a step-sectioning procedure, 
with or without immunohistochemical staining. However, as could 
be expected, intensive examination of sentinel lymph nodes 
resulted in an increased detection of small metastatic tumor de-
posits, including isolated tumor cells and micrometastases (13), 
and reopened the discussion on the prognostic value of these small 
tumor deposits.
Before the sentinel lymph node era, all tumor deposits of 2 mm 
or less in diameter were classified as lymph node–positive micro-
metastatic disease. However, the Cancer Staging Manual of the 
American Joint Committee on Cancer (6th edition) in 2002 (14) dis-
tinguished between isolated tumor cells and micrometastases 
because of doubt about the prognostic relevance of isolated tumor 
cells (6,15–18). Isolated tumor cells are defined as tumor cell clus-
ters that are not more than 0.2 mm in largest diameter and are 
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single-section examination was associated with poorer disease-free and overall survival.
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denoted as lymph node negative (pN0[i+]). Micrometastases are 
defined as metastases that are larger than 0.2 mm in diameter but 
2 mm or smaller, denoted as lymph node positive (pN1mi).
Systematic reviews (19,20) have been published on the chance 
of additional nonsentinel lymph node involvement. The chance of 
an additional nonsentinel lymph node metastasis was approxi-
mately 20% among patients with micrometastases in the sentinel 
lymph nodes (19) and 12% among patients with isolated tumor 
cells in the sentinel lymph nodes (20). Although several reviews 
(21–31) have been published on the association between isolated 
tumor cells and micrometastases in lymph nodes and survival, none 
have given a complete overview of existing evidence in a systematic 
way. In this systematic review, we evaluated the association 
between occult metastases, isolated tumor cells, and micrometasta-
ses in axillary lymph nodes of patients with invasive breast cancer 
and disease-free and overall survival.
Patients and Methods
Literature Search Strategy
We used a protocol according to guidelines for systematic re -
views in health care (32) to carry out this systematic review. The 
literature search was conducted in MEDLINE (from January 1, 
1977, through August 1, 2008), EMBASE (from January 1, 1980, 
through August 11, 2008), and the Cochrane Library (from issue 
1, January 1, 1996, through issue 3, July 1, 2008). The search 
strategy included the following key words that could be variably 
combined: breast cancer, (sentinel) lymph node(s), isolated 
tumor cell(s), micrometastases, occult metastases, prognosis, 
survival rate, mortality, survival analysis, cause of death, disease-free 
survival, recurrence, and follow-up prediction. All papers in English, 
German, French, and Dutch were considered. Additionally, the ref-
erence lists of selected papers were searched for additional papers.
Study Inclusion Criteria
The following criteria were applied to the papers that were identi-
fied by the literature search. Studies were included if patients with 
occult metastases, isolated tumor cells, or micrometastases in axillary 
lymph nodes were compared with lymph node–negative patients, 
after a sentinel lymph node procedure and/or axillary lymph node 
dissection. Endpoints had to be described in terms of disease-free 
survival, breast cancer–specific survival, or overall survival. Studies 
that did not evaluate survival outcomes by life-table analyses or 
Kaplan–Meier methods were excluded. An exception was made for 
studies in patients who had undergone a sentinel lymph node pro-
cedure (ie, sentinel lymph node biopsy studies), in which survival 
analyses were rarely carried out because the follow-up time was 
short. Studies that reported on detection methods by use of molec-
ular biology approaches (such as reverse transcriptase–polymerase 
chain reaction) and studies in which neoadjuvant chemotherapy was 
administered were excluded. If duplicate or updated studies were 
identified, only the more recent study was included. Only full papers 
that were based on original data were included.
Data Collection
Two independent investigators (M. de Boer and J. A. A. M. van 
Dijck) extracted data to rule out potential bias or errors. 
cONteXt AND cAVeAtS
Prior knowledge
Introduction of the sentinel lymph node biopsy procedure has 
increased interest in the prognostic value of isolated tumor cells 
and micrometastases in lymph nodes from patients with breast 
cancer.
Study design
Systematic review of the literature on the association of isolated 
tumor cells and micrometastases in lymph nodes with survival that 
were reported from three study types: cohort studies with single-
section pathological examination of axillary lymph nodes, retro-
spective examination of negative lymph nodes by step sectioning 
and/or immunohistochemistry, and sentinel lymph node biopsy 
studies with intensified work-up of the sentinel but not of the non-
sentinel lymph nodes.
Contribution
The presence (vs the absence) of metastases that were 2 mm or 
less in diameter in axillary lymph nodes was associated with 
poorer overall survival among cohort studies and with poorer over-
all survival and 5-year disease-free survival among occult metasta-
ses studies, although these last two endpoints were not consistently 
assessed in multivariable analyses. Conclusions could not be 
drawn from sentinel lymph node biopsy studies because studies 
were limited by small patient groups and short follow-up.
Implications
Additional studies are required to determine the association 
between metastases of 2 mm or less in diameter in sentinel lymph 
nodes and survival.
Limitations
Most studies in this review did not carry out multivariable analyses 
because of their small size. Individual treatment data were not 
available from many studies.
From the Editors
 
Discrepancies were resolved by consensus and if necessary by dis-
cussion with a third investigator (V. C. G. Tjan-Heijnen). The 
following data were extracted from the included papers: patholog-
ical assessment of removed lymph nodes; definition of isolated 
tumor cells, micrometastases, and occult metastases; number of 
patients without metastases; number of patients with lymph nodes 
containing isolated tumor cells, micrometastases, or occult metas-
tases; included stages of disease; duration of follow-up; adminis-
tration of adjuvant systemic therapy; performance of axillary 
lymph node dissection; definition of endpoints; disease-free, 
breast cancer–specific, and/or overall survival rates; and results of 
and factors taken into account in multivariable analyses. When 
data with respect to survival were not provided in text or a table of 
an article, they were extracted from the survival curves. Some 
studies did not report on exact data with respect to outcome of 
statistical analyses and only reported that there was no statistically 
significant difference in survival between the lymph node–negative 
and lymph node–positive group. Therefore, a complete dataset 
could not always be obtained for every study group evaluated in 
each study.
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Study Categories
We categorized the included studies according to the method for 
pathological assessment of the lymph nodes, including single or 
multiple sectioning with or without immunohistochemical stain-
ing. In this way, we aimed to show more clearly the differences and 
similarities between previous and current practice, which includes 
the sentinel lymph node procedure. We additionally categorized 
studies according to study type. The first category contained 
cohort studies of patients with micrometastases and/or isolated 
tumor cells that were detected through a single-section histolog-
ical examination without routine use of immunohistochemical 
staining. The second category contained occult metastases studies 
of patients who were lymph node negative by histological exami-
nation of axillary lymph nodes but had occult metastases (including 
isolated tumor cells, micrometastases, and macrometastases) by 
retrospective pathological examination that included step sec-
tioning and/or immunohistochemical staining. The third category 
contained sentinel node biopsy studies of patients who underwent 
a sentinel lymph node biopsy optionally followed by an axillary 
lymph node dissection. In most of the sentinel lymph node biopsy 
studies, the sentinel lymph node(s) were evaluated by step sec-
tioning with or without immunohistochemical staining, whereas 
the nonsentinel lymph nodes were evaluated in a single section 
that was stained with hematoxylin–eosin.
Statistical Analysis
For each cohort study or occult metastases study, we calculated 
the 5- and 10-year relative risk (RR) of disease recurrence and/
or death from any cause for the group with metastases that had a 
diameter of 2 mm or less or the group with occult metastases; the 
comparison group for both analyses was the lymph node–negative 
group. We used random-effects meta-analyses to calculate pooled 
estimates of the relative risks of 5- and 10-year disease recur-
rence and death. For some studies, the relative risks were an 
estimation because they had to be deduced from the Kaplan–
Meier curves, and therefore, the standard error of the estimate 
could not be determined accurately. In that case, we estimated 
the lower and the upper boundary for the standard error and 
used the average of the two to carry out the meta-analysis. In a 
sensitivity analysis, we repeated the meta-analyses that were 
based on the standard errors that varied between the boundaries. 
To prevent overlap of data from studies that described subpopu-
lations besides a total population (7,10,33,34), only the total 
population was taken into account for calculation of the pooled 
estimates of the relative risks. For cohort studies that were based 
on overlapping selections from the Surveillance, Epidemiology, 
and End Results database (35–37), only the largest study was 
used for calculation of the pooled hazard ratio (HR) (35). For the 
cohort studies that reported the results of a multivariable pro-
portional hazard analysis, we pooled the hazard ratios of overall 
survival that were associated with the presence of metastases 
with a diameter of 2 mm or less by use of a random-effects ap-
proach. The heterogeneity index (I2) was used to evaluate incon-
sistency between the study results (38). We reported 95% 
confidence intervals (CIs). All analyses were performed in SAS 
(version 8.2) (SAS Institute, Cary, NC) (39). All statistical tests 
were two-sided.
results
Literature Search
The systematic literature search yielded 953 articles. After screening 
of abstract and title, full texts of 129 articles were obtained and 45 
articles were selected on the basis of the described selection crite-
ria. Four articles (40–43) were excluded because they were based 
on the same study populations as other, more recent, articles. 
Five additional articles (16,17,44–46) were included that were 
identified by the manual review of references of selected articles. 
Consequently, 46 articles were included. Of these 46 articles, nine 
(7,10,11,15,16,33,34,47,48) reported data on 21 populations and 
37 (3–6,8,9,18,35–37,44,49–52,53–74) reported data on 37 popula-
tions. All populations were regarded as separate studies, resulting 
in the inclusion of 58 studies (with 297 533 patients) for further 
evaluation in this systematic review. Twelve studies in 10 articles 
(34–37,44,47,49–52) were categorized as cohort studies (with 
285 638 patients); 37 studies in 27 articles (3–11,15,16,18,33,48,53–
65) were categorized as occult metastases studies (with 7740 
patients); and nine studies in nine articles (66–74) were categorized 
as sentinel lymph node biopsy studies (with 4155 patients).
Cohort Studies
Characteristics of the 12 cohort studies included in this review are 
shown in Table 1. Except for Colleoni et al. (50), these studies 
defined micrometastases as metastases of 2 mm or less in diameter. 
No distinction was made between micrometastases and isolated 
tumor cells, as opposed to the current definition of micrometasta-
ses (which is tumor deposit[s] >0.2 mm and ≤2 mm in size) and 
isolated tumor cells (which is tumor deposit[s] ≤0.2 mm) in the 
sixth edition of the Cancer Staging Manual (14). Colleoni et al. (50) 
distinguished micrometastases (from >0.2 to ≤2 mm in diameter) 
from isolated tumor cells (≤0.2 mm in diameter) but analyzed iso-
lated tumor cells and micrometastases as one group. In all studies, 
axillary lymph node dissections were carried out without previous 
sentinel lymph node biopsy procedures, except in the studies of 
Colleoni et al. (50) and Chen et al. (35). In these studies, 43% and 
28%, respectively, of the patients had undergone a sentinel lymph 
node biopsy procedure that could be followed by an axillary lymph 
node dissection. Because most patients had undergone an axillary 
lymph node dissection only, we included these two studies in the 
cohort studies instead of in the sentinel lymph node biopsy studies. 
The axillary (nonsentinel) lymph nodes were examined by use of 
hematoxylin–eosin staining in one level without step sectioning; 
however, in one study (52), immunohistochemical staining was 
used in case of doubt.
The included study populations were heterogeneous with 
respect to breast cancer stage, ranging from stage I (37,47) to stage 
III (51). The median follow-up in these studies was 10 years (range = 
4.1–16.7 years). Whether or not adjuvant systemic therapy had been 
administered was not reported in eight (35–37,44,47,49,51) of 12 
studies.
Disease-free survival from univariate analyses was reported in 
four studies (44,47,50). Nine studies reported the 5-year overall 
survival from univariate analyses (34,35,37,44,49–52), and all but 
two (44,50) showed a worse 5-year overall survival in the group 
with metastases that were 2 mm or less in diameter than in the 
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lymph node–negative group (Figure 1, A) (pooled estimate for RR 
of death = 1.39, 95% CI = 1.19 to 1.62; I2 = .38). Eight cohort studies 
reported the 10-year overall survival (34–37,49,51,52), and all found 
a worse survival in the group with metastases that were 2 mm or less 
in diameter than in the lymph node–negative group (Figure 1, B) 
(pooled estimate for RR of death = 1.21, 95% CI = 1.13 to 1.30; 
I2 = .17). The results of the sensitivity analyses were similar.
In all seven studies (34–37,50,52) that carried out multivariable 
analyses, primary tumor size was taken into account in a model 
that also contained the presence of metastases that were 2 mm or 
less in diameter. Age or menopausal status was taken into account 
in six studies (34–37,52). In three studies (35,37,50), tumor grade 
and/or hormone receptor status were taken into account. One 
study (37) carried out multivariable analysis on the prognostic 
impact on breast cancer–specific survival of metastases that were 
2 mm or less in diameter. Six studies (34–36,50,52) carried out 
multivariable analyses of the prognostic value of metastases of 2 
mm or less in diameter on overall survival (Figure 2), 
five (34–36,52) of which showed a negative prognostic impact 
on overall survival of metastases that were 2 mm or less in diam-
eter (from a pooled analysis, HR of death for the presence of 
metastases that were 2 mm or less in diameter = 1.44, 95% CI = 
1.29 to 1.62; I2 = .34).
Only one study (34) included a population that had been treated 
either with or without adjuvant systemic therapy, with separate 
analyses per subgroup. The presence of metastases that were 2 mm 
or less in diameter was associated with lower overall survival in the 
total population (HR of death = 1.32, 95% CI = 1.03 to 1.69). 
However, in the subpopulation that had not been treated with 
adjuvant systemic therapy and contained 49% of the total popula-
tion, the presence of metastases that were 2 mm or less in diameter 
was associated with even lower overall survival (HR of death = 
1.51, 95% CI = 1.11 to 2.06).
Occult Metastases Studies
Characteristics of the 37 occult metastases studies 
(3–11,15,16,18,33,48,53–65) included in this review are shown in 
Table 2. The pathological assessment of the axillary lymph nodes in 
the occult metastases studies was very heterogeneous. In six studies 
(3,15,18,57,64), step sectioning was carried out; in 18 studies 
(5,7,9–11,33,53,55,59–61), step sectioning was combined with im-
munohistochemical staining; and in 13 studies (4,6,8,16,48,54,56,58,
62,63,65), only immunohistochemical staining was carried out. The 
sizes of the occult metastases were heterogeneous, ranging from 
single tumor cells (10,33) to macrometastases that were 10 mm in 
diameter (7). Breast cancer stage of the included patients was not 
described in 20 studies (3,7–9,11,16,18,33,55,56,60–62,65). In 16 
studies (5,6,10,15,48,53,54,57–59,63,64), patients with stage I and/
or II disease were included. Median follow-up of the occult metas-
tases studies was 8 years (range = 3.6–24 years). Data regarding the 
administration of adjuvant systemic therapy were not reported in 
seven studies (5,6,9,16,61,62,65). Adjuvant systemic therapy was 
administered to all or some of the included patients in six studies 
(8,10,15,58), and no systemic therapy was administered in 24 studies 
(3,4,7,11,15,16,18,33,48,53–57,59,60,63,64).
After a 5-year follow-up among the group with occult metasta-
ses, compared with the lymph node–negative group, the pooled 
estimates for risk of disease recurrence (RR = 1.55, 95% CI = 1.32 
to 1.82; I 2 = .15) (Figure 3, A) and for risk of death (RR = 1.45, 95% 
CI = 1.11 to 1.88; I 2 = .17) (Figure 3, B) were similar. In an analysis 
after a 10-year follow-up that compared the same groups, the 
pooled estimates for risk of disease recurrence was similar to that 
at the 5-year follow-up (RR = 1.58, 95% CI = 1.22 to 2.05; I2 = .67) 
(Figure 4, A), but the risk of death was lower (RR = 1.31, 95% CI = 
1.05 to 1.63; I2 = .56) (Figure 4, B). The results of the sensitivity 
analyses were similar to the results above.
Separate analyses for patients with isolated tumor cells and 
patients with micrometastases were carried out in five studies 
(7,10,11,33,48). All five studies found that reduced disease-free or 
overall survival rates were associated with micrometastases, and all 
but one study (33) found that a reduced disease-free or overall 
Figure 1. Cohort studies: association between risk of death after follow-up 
and the presence of metastases of 2 mm or less in diameter in axillary 
lymph nodes. A) A 5-year follow-up. (I2 for heterogeneity = .38.) B) A 
10-year follow-up. (I2 = .17.) Each circle indicates the magnitude of the 
relative risk (RR), and the horizontal line through the circle indicates the 
95% confidence interval (CI). The relative risks and their 95% confidence 
intervals were combined to obtain a pooled relative risk, as shown by 
the diamond and its 95% confidence interval. In both pooled analyses, 
the studies marked with an asterisk were not taken into account. The 
study of Kuijt et al. (34) in patients without adjuvant systemic therapy 
(AST) was not taken into account because it was based in part on the 
same population as in the total population of that study. The studies of 
Maibenco et al. (37) and Truong et al. (36) were not taken into account 
because they were in part based on the same population as in the study 
of Chen et al. (35).
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Figure 2. Cohort studies: multivariably cor-
rected associations between overall survival 
(OS) and lymph nodes containing metastases 
of 2 mm or less in diameter vs lymph nodes 
with no metastases. (I2 for heterogeneity = 
.34.) Hazard ratios (HR, circles) and 95% confi-
dence intervals (95% CIs, horizontal line 
through circles) were abstracted from each 
study and combined to obtain a pooled esti-
mate of the association between the presence 
of micrometastases in lymph nodes and OS 
(diamond). Studies marked with an asterisk 
were not taken into account in the pooled 
analysis. The study of Truong et al. (36) was 
not taken into account because it was based 
in part on the same population as that used in 
the study of Chen et al. (35); the study of Kuijt 
et al. (34) in patients without adjuvant systemic 
therapy (AST) was not taken into account 
because it was based in part on the same 
population that was analyzed in the total 
study group of that study.
survival rate was associated with isolated tumor cells; the compar-
ison group for both studies was the lymph node–negative group.
The impact of occult metastases on disease-free survival was 
determined by multivariable analyses in only 12 (3,5,6,8,9, 
11,33,48,53,61,63) of the 37 occult metastases studies, eight 
(3,5,9,11,33,53,61,63) of which found no negative impact. In mul-
tivariable analyses, in three (4,11,61) of six (4,8,11,48,61) studies 
on the impact of occult metastases on overall survival, occult 
metastases had no negative impact. Most of the studies (3–
5,33,61,63) that carried out multivariable analyses on disease-free 
and/or overall survival and found no negative impact described the 
impact as “not [statistically] significant” without providing specific 
results. Therefore, we could not pool the results of multivariable 
analyses from these studies.
Sentinel Lymph Node Biopsy Studies
Characteristics of the nine sentinel lymph node biopsy studies 
(66–74) are shown in Table 3. Eight studies (67–74) processed the 
sentinel lymph nodes by using step sectioning and immunohisto-
chemical staining; in one study (66), only step sectioning was used. 
In six studies (66–68,70,71,73), no details on the breast cancer 
stage of included patients were reported. Median follow-up of the 
patients in all sentinel lymph node biopsy studies was 3 years 
(range = 1.2–6.1 years). Data regarding the administration of adju-
vant systemic therapy were not reported in four studies 
(66,68,69,72). In five studies (67,70,71,73,74), adjuvant systemic 
therapy was administered to a part of the patient population. Only 
one study (74) carried out multivariable analyses, in which the 
impact of systemic therapy was taken into account. With exception 
of the studies of Cox et al. (73) (that included 273 patients) and 
Gobardhan et al. (74) (that included 99 patients), almost all studies 
were small, including up to 45 patients who had lymph nodes 
containing isolated tumor cells or micrometastases. Four studies 
carried out survival analyses: one (74) was based on final lymph 
node status and three (67,70,73) were based on sentinel lymph node 
status. In all nine studies, the proportion of axillary lymph 
node dissection ranged from 0% to 100% in patients with isolated 
tumor cells or micrometastases and from 0% to 44% in patients 
with lymph node–negative disease.
Five studies (66–68,70,71) considered patients with microme-
tastases and isolated tumor cells as one group and found no reduced 
recurrence-free survival rates for these patients as compared with 
lymph node–negative patients, although the rates were not statisti-
cally tested in one study (68). Two studies (72,73) carried out sep-
arate analyses for patients with isolated tumor cells. One study (72) 
(with 145 patients in total and six with isolated tumor cells) found 
a higher recurrence rate in patients with isolated tumor cells, but a 
survival analysis was not carried out because of small numbers of 
patients and events. The other larger study (73) (with 2381 patients 
in total and 151 with isolated tumor cells) did not find a lower 
relapse-free survival rate for patients with isolated tumor cells.
Four studies (69,72–74) assessed the prognostic impact of micro-
metastases (that were >0.2 mm but ≤2 mm in diameter). Statistical 
analyses were not carried out in two studies (69,72). Two studies 
(72,73) reported a higher recurrence rate for patients with microme-
tastases; however, results were based on sentinel lymph node status, 
and additional macrometastatic disease was found in some patients 
after axillary lymph node dissection. The other two studies (69,74) 
reported no reduced survival rates for these patients. Only the data in 
Gobardhan et al. (74) were based on final lymph node status. Although 
they did not find that the presence of micrometastases had a negative 
prognostic impact on disease-free and overall survival, they did find 
an increased risk of distant metastases among patients with microme-
tastases as final lymph node status (HR of distant metastases = 4.85, 
95% CI = 1.79 to 13.18) compared with patients who were lymph 
node negative or who had isolated tumor cells. Random-effects meta-
analyses to calculate pooled estimates of the relative risks could not be 
carried out because of the few studies that carried out survival analyses 
and because the follow-up in such studies was short.
Discussion
In this systematic review, we analyzed the association between 
presence of micrometastases and isolated tumor cells and outcome 
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Figure 3. Occult metastases studies: 
associations between risk of disease 
recurrence or death after a 5-year 
follow-up and the presence of occult 
metastases in axillary lymph nodes. 
A) Risk of disease recurrence. (I 2 for 
heterogeneity = .15.) B) Risk of death. 
(I 2 = .17.) Circles indicate the relative 
risk (RR). The horizontal line through 
the circle indicates the 95% confi-
dence interval (CI) of that relative 
risk. The relative risks and their 95% 
confidence intervals were combined 
to obtain a pooled relative risk (dia-
mond). For both pooled analyses, 
the studies marked with an asterisk 
were not taken into account. The 
studies of Nasser et al. (33), Querzoli 
et al. (10), and Millis et al. (7), which 
describe populations with isolated 
tumor cells or micrometastases, 
were not taken into account because 
these populations were included in 
the analysis of the total group in the 
corresponding study. IBCSG = 
International Breast Cancer Study 
Group; IDC = invasive ductal carci-
noma; ILC = invasive lobular carci-
noma; ITC = isolated tumor cells of 
0.2 mm or less in diameter; mi = 
micrometastases of greater than 0.2 
to 2 mm or less; peri-op CT = periop-
erative chemotherapy.
in 58 studies reported before August 11, 2008. These studies were 
categorized by the method of pathological assessment of the lymph 
nodes. In pooled analyses of long-term overall survival, we found 
that the presence of metastases of 2 mm or less in diameter, as 
detected by staining with hematoxylin–eosin in one section of each 
axillary lymph node, was associated with decreased overall survival, 
even after correction for other prognostic factors. The prognostic 
value of occult metastases (including isolated tumor cells, micro-
metastases, and macrometastases) after intensified pathological 
assessment of all axillary lymph nodes or of sentinel lymph nodes 
alone remained undetermined because of heterogeneity in meth-
odology, small sample size, or short follow-up.
After approximately 40 years, more than 50 studies have been 
carried out to clarify the prognostic impact of isolated tumor cells 
and micrometastases in axillary lymph nodes in patients with breast 
cancer, but the issue has still not been elucidated completely. Its 
relevance, however, has become a major issue since the introduc-
tion of the sentinel lymph node biopsy procedure. Because the 
sentinel lymph node is routinely examined by use of step sec-
tioning and immunohistochemical staining, isolated tumor cells 
and micrometastases are now frequently detected. Because of 
inconsistent findings in old studies, different policies on adjuvant 
systemic therapy are recommended by the American Society of 
Clinical Oncology, the St Gallen Breast Cancer Treatment 
Consensus, and the Dutch Treatment of Breast Cancer Guideline 
Group in patients who have otherwise favorable primary tumor 
characteristics (12,75,76). To our knowledge, we are the first to 
use a systematic review to analyze the evidence that these small 
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Figure 4. Occult metastases studies: 
association between risk of disease 
recurrence and death after a 10-year 
follow-up and the presence of occult 
metastases in axillary lymph nodes. 
A) Risk of disease recurrence. (I 2 for 
heterogeneity = .67.) B) Risk of death. 
(I 2 = .56.) Circles indicate the relative 
risk (RR). The horizontal line through 
a circle indicates the 95% confidence 
interval (95% CI) of that relative risk. 
The relative risks and their 95% con-
fidence intervals were combined to 
obtain a pooled relative risk (dia-
mond). For both pooled analyses, 
studies marked with an asterisk were 
not taken into account. The studies of 
Nasser et al. (33) and Millis et al. (7), 
which describe populations with iso-
lated tumor cells or micrometasta-
ses, were not taken into account 
because these populations were in-
cluded in the analysis of the total 
group of the corresponding studies. 
IDC = invasive ductal carcinoma; ILC = 
invasive lobular carcinoma; ITC = 
isolated tumor cells of 0.2 mm or less 
in diameter; mi = micrometastases of 
greater than 0.2 to 2 mm or less.
lymph node metastases are associated with disease-free survival 
and overall survival among patients with invasive breast cancer. 
The ultimate aim of this systematic review was to provide guidance 
for present practice that is based on previous studies.
The cohort studies (34–37,44,47,49–52) that we analyzed in 
this study included almost all patients who had been diagnosed 
with breast cancer before the introduction of the Cancer Staging 
Manual in 2002 (14). Therefore, micrometastases were considered 
to be deposits of tumor cells that were 2 mm or less in diameter, 
and no distinction was made between micrometastases and isolated 
tumor cells (≤0.2 mm in diameter) and micrometastases (from >0.2 
mm in diameter to ≤2 mm). In pooled analyses, the presence of 
metastases with a diameter of 2 mm or less was associated with 
decreased overall survival (HR of death = 1.44, 95% CI = 1.29 to 
1.62), after correction for other prognostic factors. These known 
prognostic factors were, in general, more important prognostic 
factors than the presence of micrometastases.
In the occult metastases studies (3–11,15,16,18,33,48,53–65) 
that we analyzed in this study, most sample sizes of patients with 
occult metastases were small. In general, after 5 years of follow-up, 
an occult metastasis status was associated with worse survival than 
a lymph node–negative status (pooled RR of disease recurrence = 
1.55, 95% CI = 1.32 to 1.82; and pooled RR of death = 1.45, 95% 
CI = 1.11 to 1.88). The occult metastases studies were heteroge-
neous with respect to pathological assessment, patient population, 
duration of follow-up, and methodology. Despite this heteroge-
neity, results of the studies were fairly homogenous, and the 
pooled estimate was inside the confidence intervals of all studies. 
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Multivariable analyses were carried out infrequently and did not 
consistently confirm the univariate results. We were not able to 
calculate pooled hazard ratios for the occult metastases studies 
because of the lack of data with respect to multivariable analyses.
The sentinel lymph node biopsy studies (66–74) that we ana-
lyzed in this study could have provided evidence for or against an 
association between outcome and the presence of isolated tumor 
cells and micrometastases that are detected by use of current 
protocols. However, the studies in this analysis were hampered 
by small numbers of patients, short follow-up times, analyses that 
were based on sentinel lymph node status, and lack of multivari-
able analyses. The only study (74) in this group of studies that 
carried out a multivariable analysis did not report a negative as-
sociation of micrometastases (from >0.2 to ≤2 mm) with disease-
free and overall survival, although an almost five times higher risk 
for the presence of distant metastases (HR of distant metastases = 
4.85, 95% CI = 1.79 to 13.18) being associated with the presence 
of micrometastases was reported. If the cohort studies (35,50) in 
which sentinel lymph node biopsies were performed in a part of 
the patient population were taken into account in the category 
of sentinel lymph node biopsy studies, the presence of metastases 
of 2 mm or less in diameter in (sentinel) axillary lymph nodes 
was associated with lower disease-free survival (50) and overall 
survival (35).
In the cohort studies, it should be noted that the axillary lymph 
nodes were generally processed only by use of a single section that 
was stained with hematoxylin–eosin. In the past, the practice in 
many pathology departments was to slice any lymph node in half 
when it was too large to fit into a cassette, and so only one half of 
the lymph node was examined. When a lymph node was found to 
be negative after hematoxylin–eosin staining at one level, addi-
tional step sectioning with hematoxylin–eosin staining and/or im-
munohistochemical staining was used. By this method, occult 
metastases were detected in 9% to 42% of patients (3–
11,15,16,18,33,48,53–65), depending on the level of detail of the 
work-up. The frequency of detection of small metastases increases 
with a more detailed work-up (77,78). In sentinel lymph nodes, 
approximately 40% of positive lymph nodes were found to have 
been missed when lymph nodes are grossly bisected and then one 
routine histological section was examined from each lymph node 
half (79). Therefore, in the cohort studies, the lymph node–negative 
groups might have contained patients with undetected (macro)
metastases.
From the occult metastases studies (3–11,15,16,18,33,48,53–65) 
and from the sentinel lymph node biopsy studies (66–74), the dis-
tinct impact of systemic adjuvant therapy on survival could not be 
determined. In fact, the use of adjuvant systemic therapy may have 
obscured a true difference in survival rates in some studies because 
we were not able to consider this confounding parameter in the 
analyses. Among the cohort studies, Kuijt et al. (34) found that 
patients with metastases of 2 mm or less in diameter who were not 
treated with adjuvant systemic therapy had a higher risk of mor-
tality than all patients, 51% of whom had received systemic adju-
vant therapy. The results of this small study underline the 
importance of studying the relationship of micrometastases and 
isolated tumor cells to prognosis among patients who have not 
received adjuvant systemic therapy.
This study had several limitations. Most studies did not carry 
out multivariable analyses because they were too small to obtain a 
meaningful result. Future studies on prognostic factors should be 
powered to obtain meaningful conclusions. It should be recog-
nized that, in systematic reviews and pooled analyses that are based 
on published data, there is always the drawback of lack of indi-
vidual patient data with missing information (eg, treatment infor-
mation). This lack of treatment information would tend to 
underestimate of the risk because patients with micrometastases 
would be more likely to receive chemotherapy. In addition, biases 
in reported nonrandomized studies carry over to this current 
analysis because we have used the results of these studies in our 
pooled analyses. Finally, publication bias would also tend to over-
estimate the risk because negative studies would be less likely to be 
submitted for publication.
Because of nonstandardized pathological examinations of lymph 
nodes across studies, comparison of the results from cohort and 
occult metastases studies with studies that use the sentinel lymph 
node procedure and an extensive pathological examination, which 
is currently common practice, is difficult. Nevertheless, although 
the studies included in this systematic review were limited by sev-
eral methodological problems, we have shown that small metasta-
ses appear to be associated with worse outcome. Ongoing or 
recently closed sentinel lymph node trials will hopefully provide 
definitive data regarding the relationship of micrometastases and 
isolated tumor cells to breast cancer prognosis.
Results from the International Breast Cancer Study Group 
23-01 study (80) should provide data to determine whether meta-
static involvement of 2 mm or less in diameter in sentinel lymph 
nodes of patients with clinically lymph node–negative breast can-
cer is associated with prognosis. The American College of 
Surgeons Oncology Group Z0011 trial among patients with stage 
I or IIA breast cancer is evaluating the prevalence and prognostic 
significance of micrometastases and isolated tumor cells, as 
detected by immunocytochemistry, in the sentinel lymph node and 
in the bone marrow (81). Unfortunately, this trial has been stopped 
because of poor accrual. The National Surgical Adjuvant Breast 
and Bowel Project Protocol B-32 (82) is evaluating among patients 
who are sentinel lymph node–negative by routine pathological as-
sessment whether a more detailed pathology investigation of sen-
tinel lymph nodes can identify a group of patients with a potentially 
increased risk of systemic recurrence. The last study on this topic 
is the Micrometastasis and Isolated Tumor Cells: Relevant and 
Robust or Rubbish Trial from the Dutch Breast Cancer Trialists’ 
Group (83). A preliminary report from this study found that the 
presence of both isolated tumor cells and micrometastases as final 
lymph node status was negatively associated with disease-free sur-
vival among patients who had undergone a sentinel lymph node 
procedure and did not receive systemic adjuvant therapy; however, 
if patients with isolated tumor cells and micrometastases received 
systemic adjuvant therapy, disease-free survival improved.
In conclusion, since the introduction of the sentinel lymph 
node procedure in the late 1990s, interest has been renewed in the 
association of isolated tumor cells and micrometastases with prog-
nosis. To our knowledge, we are the first to evaluate systematically 
the impact of these small lymph node metastases on disease-free 
survival and overall survival among patients with invasive breast 
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cancer. We found in pooled analyses of long-term overall survival 
that the presence of metastases of 2 mm or less in diameter, as 
detected by staining with hematoxylin–eosin in one section of each 
axillary lymph node and without differentiation between isolated 
tumor cells and micrometastases, was negatively associated with 
prognosis. The independent prognostic value of occult metastases 
(including isolated tumor cells, micrometastases, and macrometasta-
ses) after intensive pathological assessment of all axillary lymph nodes 
remained undetermined. Because of nonstandardized pathological 
examination, the translation of the evidence from these older studies 
to the current practice of intensified examination of the sentinel 
lymph node but conventional examination of the nonsentinel lymph 
nodes is limited. In addition, studies in the sentinel lymph node era 
that have been published in peer-reviewed journals are hampered 
by small sample size and short follow-up. Therefore, results of the 
ongoing sentinel lymph node studies are eagerly awaited to provide 
data on the association of isolated tumor cells and micrometastases 
with prognosis and on the need for systemic adjuvant therapy.
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